Browse result page of CancerPDF Database

Please click on CancerPDF_ID for detailed information about peptide.

CancerPDF_IDPeptide seqProtein NameFluidMass/ZProfiling TechniqueCancer Type Expression RegulationPUBMED ID
CancerPDF_ID34 NGFKSHALQLNComplement C4 precursorSerum1228.65MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID35 NGFKSHALQLNNRComplement C4 precursorSerum1498.91MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID36 NGFKSHALQLNNRQComplement C4 precursorSerum1626.85MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID37 NGFKSHALQLNNRQIComplement C4 precursorSerum1739.93MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID38 NGFKSHALQLNNRQIRComplement C4 precursorSerum1895.99MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID39 GLEEELQFSLGSKINVComplement C4 precursorSerum1762.87MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID40 GLEEELQFSLGSKINVKVGGNSComplement C4 precursorSerum2305.2MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID41 GLEEELQFSLGSKINVKVGGNSKGTLComplement C4 precursorSerum2704.13MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID42 GLEEELQFSLGSKINVKVGGNSKGTLKVLRComplement C4 precursorSerum3200.52MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID43 TLEIPGNSDPNMIPDGDFNSYVRComplement C4 precursorSerum2551.06MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID44 TLEIPGNSDPNFIPDGDFNSYVRComplement C4 precursorSerum856.33MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID45 PDGDFNSYVRComplement C4 precursorSerum585.23MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID873 TLEIPGNSDPNMIPDGDFNSYVRComplement C4-APlasma"1276.08, 851.05"LC-MSDuctal adenocarcinoma of the pancreas (DAP) NA 19795908
CancerPDF_ID1050 NGFKSHALQLNNRComplement C4 precursorSerum1498.91MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 809 and 1 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1051 NGFKSHALQLNNRQComplement C4 precursorSerum1626.85MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.09, 0.88 and 2.78 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1052 NGFKSHALQLNNRQIComplement C4 precursorSerum1739.93MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.75, 0.66 and 2.75 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1053 NGFKSHALQLNNRQIRComplement C4 precursorSerum1895.99MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.27, 3.33 and 2.95 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1054 GLEEELQFSLGSKINVComplement C4 precursorSerum1762.87MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.62, 0.01 and 3.16 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1055 GLEEELQFSLGSKINVKVGGNSComplement C4 precursorSerum2305.2MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.75, 2.56 and 3.49 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1056 GLEEELQFSLGSKINVKVGGNSKGTLComplement C4 precursorSerum2704.13MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =61, 49 and 133 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1057 GLEEELQFSLGSKINVKVGGNSKGTLKVLRComplement C4 precursorSerum3200.52MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1058 TLEIPGNSDPNMIPDGDFNSYVRComplement C4 precursorSerum2551.06MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1923 QGSFQGGFRComplement C4-ASerum982.46208LC-MSColorectal cancer NA 21136997
CancerPDF_ID3157 SHALQLNNComplement C4-APlasma895.4512LC-MSNormal NA 21136997
CancerPDF_ID3158 SHALQLNNRComplement C4-APlasma1051.5523LC-MSNormal NA 21136997
CancerPDF_ID3159 VGGNSKGTLKVLComplement C4-APlasma1171.6925LC-MSNormal NA 21136997
CancerPDF_ID3160 VGGNSKGTLKVLRComplement C4-APlasma1327.7936LC-MSNormal NA 21136997
CancerPDF_ID3161 SHALQLNNRQIRComplement C4-APlasma1448.796LC-MSNormal NA 21136997
CancerPDF_ID3162 NGFKSHALQLNNRComplement C4-APlasma1497.7801LC-MSNormal NA 21136997
CancerPDF_ID3163 YALLHLLLHEGKAEMComplement C4-APlasma1736.9284LC-MSNormal NA 21136997
CancerPDF_ID3164 QIRGLEEELQFSLGSKComplement C4-APlasma1832.9632LC-MSNormal NA 21136997
CancerPDF_ID3165 QIRGLEEELQFSLGSKINVComplement C4-APlasma2159.1586LC-MSNormal NA 21136997
CancerPDF_ID3166 ALEILQEEDLIDEDDIPVRComplement C4-APlasma2224.1111LC-MSNormal NA 21136997
CancerPDF_ID3167 LDHRGRTLEIPGNSDPNMIPDGComplement C4-APlasma2403.1601LC-MSNormal NA 21136997
CancerPDF_ID3168 TLEIPGNSDPNMIPDGDFNSYVRComplement C4-APlasma2550.1697LC-MSNormal NA 21136997
CancerPDF_ID3169 GRTLEIPGNSDPNMIPDGDFNSYVComplement C4-APlasma2607.1911LC-MSNormal NA 21136997
CancerPDF_ID3170 GRTLEIPGNSDPNMIPDGDFNSYVRComplement C4-APlasma2763.2922LC-MSNormal NA 21136997
CancerPDF_ID3171 VLQIEKEGAIHREELVYELNPLDHRComplement C4-APlasma2999.5829LC-MSNormal NA 21136997
CancerPDF_ID3172 VLQIEKEGAIHREELVYELNPLDHRGComplement C4-APlasma3056.6043LC-MSNormal NA 21136997
CancerPDF_ID8672 AACAQLNDFLQEYGTQGCQVComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8715 AQLNDFLQEYGTQGCQVComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8717 ARVQQPDCREPFLSCCQFAESComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8731 CCQDGVTRLPMComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8737 DCREPFLSCComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8738 DCREPFLSCCComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8739 DCREPFLSCCQComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8743 DDPDAPLQPVTPLQLFEGComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8746 DFNSYVRVComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8749 DGDFNSYVRVComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9220 SDPNMIPDGDFComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9305 TLEIPGNSDPNMIPDGDFComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9306 TLEIPGNSDPNMIPDGDFNSComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9405 VQQPDCREPFLSCCQFAESComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9447 YVRVTASDPLDComplement C4-AAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9453 SHALQLNNRComplement C4-A/Complement C4-BPlasma1052.56MALDI-TOFColorectal cancer "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " 26379225
CancerPDF_ID9458 LQLNNRQIRComplement C4-A/Complement C4-BPlasma1154.68MALDI-TOFColorectal cancer "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " 26379225
CancerPDF_ID9460 ALQLNNRQIRComplement C4-A/Complement C4-BPlasma1225.72MALDI-TOFColorectal cancer "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " 26379225
CancerPDF_ID9466 GLEEELQFSLGSKComplement C4-A/Complement C4-BPlasma1436.72MALDI-TOFColorectal cancer Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. 26379225
CancerPDF_ID9467 SHALQLNNRQIRComplement C4-A/Complement C4-BPlasma1449.77MALDI-TOFColorectal cancer Lower intensity in liver metastasis group than adenoma and CRC groups 26379225
CancerPDF_ID9469 NGFKSHALQLNNRComplement C4-A/Complement C4-BPlasma1499.79MALDI-TOFColorectal cancer Lower intensity in liver metastasis group than adenoma and CRC groups 26379225
CancerPDF_ID9476 GFKSHALQLNNRQIRComplement C4-A/Complement C4-BPlasma1782MALDI-TOFColorectal cancer Higher intensity in liver metastasis than adenoma and CRC groups. 26379225
CancerPDF_ID9479 GLEEELQFSLGSKINVKComplement C4-A/Complement C4-BPlasma1891.02MALDI-TOFColorectal cancer "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." 26379225
CancerPDF_ID9480 NGFKSHALQLNNRQIRComplement C4-A/Complement C4-BPlasma1896.03MALDI-TOFColorectal cancer "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." 26379225
CancerPDF_ID9481 NGFKSHALQLNNRQIR(NH4)Complement C4-A/Complement C4-BPlasma1913.01MALDI-TOFColorectal cancer "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." 26379225
CancerPDF_ID9492 GLEEELQFSLGSKINVKVGGNSKComplement C4-A/Complement C4-BPlasma2433.3MALDI-TOFColorectal cancer "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." 26379225
CancerPDF_ID9610 GFKSHALQLNNRQComplement C4-ASerum504.93LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9611 GFKSHALQLNNRQIComplement C4-ASerum542.63LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9612 NGFKSHALQLNNRQComplement C4-ASerum542.95LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9613 HALQLNNComplement C4-ASerum405.2LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9614 SHALQLNNComplement C4-ASerum448.72LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9615 EEELQFSLGSComplement C4-ASerum569.76LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9616 NGFKSHALQLNNRComplement C4-ASerum500.27LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9934 NGFKSHALQLNNRQComplement C4-ASerumNALC-MSBreast cancer Differentially expressed between cancer vs control 21124649
CancerPDF_ID10354 VQLQDVPRGQVVKGSVFComplement C4-AUrine1856.0386MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10509 KPRLLLFSPSVVHLGVPLSVGComplement C4-AUrine2215.3122MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10578 NGFKSHALQLNNRQIRGLEEEComplement C4-AUrine2453.2529MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10581 VRVTASDPLDTLGSEGALSPGGVASLComplement C4-AUrine2469.2767MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID12677 DDPDAPLQPVTPLQLFEGRRNComplement C4SerumNALC-MSRenal cell carcinaoma Upregulated in cancer v/s Normal 25168216
CancerPDF_ID12710 GFKSHALQLNNRQIComplement C4Serum1625.946MALDI-TOFBreast cancer "Upregulated with the fold change of 0.68 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.78, Upregulated in BC vs healthy with 0.763 fold change" 27058005
CancerPDF_ID12711 NGFKSHALQLNNRQComplement C4Serum1626.912MALDI-TOFBreast cancer "Upregulated with the fold change of 0.56 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.80, Upregulated in BC vs healthy with 0.754 fold change" 27058005
CancerPDF_ID12712 NGFKSHALQLNNRQIComplement C4Serum1739.971MALDI-TOFBreast cancer "Upregulated with the fold change of 0.76 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.83, Upregulated in BC vs healthy with 0.796 fold change" 27058005
CancerPDF_ID12713 GFKSHALQLNNRQIRComplement C4Serum1782.012MALDI-TOFBreast cancer "Upregulated with the fold change of 1.73 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.16, Upregulated in BC vs healthy with 1.092 fold change" 27058005
CancerPDF_ID12714 NGFKSHALQLNNRQIRComplement C4Serum1896.068MALDI-TOFBreast cancer "Upregulated with the fold change of 0.45 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.00, Upregulated in BC vs healthy with 0.968 fold change" 27058005
CancerPDF_ID12757 NGFKSHALQLNNRQIRComplement C4eB-like Isoform 1Serum1898.9MALDI-TOFCervical cancer Upregulated in Cervical squamous cell carcinoma vs healthy 26282206